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8 ABSTRACT: The glycinocins are a class of calcium-dependent, acidic cyclolipopeptide antibiotics structurally related to the
9 clinically approved daptomycin. Herein, we describe a divergent total synthesis of glycinocins A−C, which differ in the structure
10 of a branched α,β-unsaturated fatty acyl moiety. The three natural products exhibited calcium-dependent antimicrobial activity
11 against Staphylococcus aureus and Bacillus subtilis with MICs ranging from 5.5 to 17 μM.
12 The glycinocins belong to a family of acidic lipopeptide13 antibiotics (including daptomycin and friulimicin) that
14 possess Ca2+-dependent antimicrobial activity.1,2 These secon-
15 dary metabolites are produced by Actinobacteria through the
16 action of nonribosomal peptide synthases, and many possess
17 significant antimicrobial activity against a range of Gram-
18 positive bacteria, including drug-sensitive and drug-resistant
19 Staphylococcus aureus strains.1,2 The recent FDA approval of
20 daptomycin3 for skin and skin structure infections, S. aureus
21 bacteraemia and S. aureus endocarditis, has prompted a
22 renewed interest in this class of compounds. Indeed, with
23 recent resistance to daptomycin observed in strains of S. aureus
24 and Enterococcus spp.,4−6 an examination of other members of
25 this natural product family, especially those that exhibit a novel
26 mechanism of action, has become of significant interest.2,7
27 Glycinocin A (1), originally named laspartomycin C, was
28 initially reported in 1967 by Naganawa et al.8,9 following
29 isolation from Streptomyces viridochromogenes. The natural
30 product was subsequently shown to have antimicrobial activity
31 against vancomycin-resistant S. aureus (VRSA) and methicillin-
32 resistant S. aureus (MRSA) strains.8−11 Kleijn et al. recently
33 proposed a putative mechanism of action of glycinocin A (1)
34 together with a synthesis of the natural product.12 Specifically,
35 the authors demonstrated the formation of a high affinity
36 complex with undecaprenyl phosphate, an essential cell wall
37 precursor in bacteria. Glycinocin A was shown to block lipid II
38 synthesis in a dose-dependent manner, thereby preventing
39 peptidoglycan synthesis which induces bacterial cell death. This
40mechanism mirrors that of fellow acidic lipopeptide antibiotic
41family members, amphomycin and friulimicin B, but differs
42from that of daptomycin.13,14 In a separate report, glycinocin A
43(1) has also been reported to reduce viral cytopathogenicity in
44herpes simplex type 1 (HSV-1) infected HeLa cells.15
45Importantly, this suggests a possible broad-spectrum poly-
46microbial activity for the family of natural products.
47Decades after its initial isolation, glycinocin A (1) was
48reisolated along with its congeners, glycinocin B (2), C (3), and
49D (4), from the fermentation broth of an unidentified terrestrial
50Actinomycete species. In this 2003 report, Kong and Carter16
51also provided the first complete structural characterization of
52glycinocins A−D (1−4). A follow-up study in 2007 by Borders
53et al.17 confirmed the structure of the Actinomycete-derived
54glycinocin A to be identical to S. viridochromogenes-derived
55laspartomycin C. Whereas the biological activities of glycinocins
56B−D (2−4) have not yet been determined, their potential as
57antibiotic leads is also worth investigating. The innate
58production of these congeners reveals a natural process of
59metabolite optimization by the producing Actinomycete species.
60It would thus be interesting to investigate the effect of
61modifying chain length, specifically in glycinocins A−C (1−3),
62on the biological activity and physiochemical properties of
63these natural products. The aim of the present study therefore
64was to conduct a total synthesis of glycinocins A−C (1−3) and
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65 to investigate the effect of the fatty acyl moiety upon biological
66 activity.
f1 67 The structure of glycinocins A−D (1−4) (Figure 1) consists
68 of a cyclodecapeptide that is bound, through an exocyclic L-Asp
69 amino acid, to a range of 2,3-unsaturated iso-fatty acids of
70 various lengths. Several features are conserved with other
71 members of the acidic lipopeptide family,2 including the
72 position of nonproteinogenic amino acids and the L-Asp-Gly-L-
73 Asp-Gly motif, which is thought to be essential for Ca2+
74 complexation.1 In glycinocins A−D (1−4), the nonproteino-
75 genic amino acid loci are occupied with L-2,3-diaminopropionic
76 acid (L-Dap), D-pipecolic acid (D-Pip), and D-allo-Thr, which
77 appear at positions 2, 3, and 9, respectively. Glycinocins A−C
78 (1−3) share a common peptidic core, which incorporates an L-
79 Ile amino acid at position 10. In contrast, glycinocin D (4)
80 possesses a L-Val amino acid at this position. The attachment of
81 these peptidic macrocycles to lipid chains confers an
82 amphipathic nature which is likely to play an important role
83 in the physiochemical properties and biological activity of
84 glycinocins A−D (1−4). However, as is common in this class
85 of natural products, and depending on the availability of fatty
86 acid precursors in the producing bacteria, various fatty acid
87 linkages are observed. Importantly, despite the difference in the
88 carbon-chain length, all attached lipids present common α,β-
89 unsaturation as well as a terminating isopropyl moiety.
90 To date, only the total synthesis of glycinocin A (1) has been
91 reported. This was achieved through the solid-phase synthesis
92 of a branched peptide precursor followed by a final step
93 macrolactamization.12 Herein, we sought a synthetic strategy
94 which would facilitate late-stage installation of the fatty acyl
95 moiety and therefore provide highly divergent access to
96 glycinocins A−C (1−3), as well as an avenue to fatty acid
97 modified analogues in the future. Retrosynthetically, we
98 envisioned that glycinocins A−C (1−3) could all be accessed
99 through solution-phase acylation of the key common protected
100 cyclic peptide precursor 5, which in turn could be accessed
101 from macrolactamization of the orthogonally protected linear
f2 102 peptide precursor 6, prepared through SPPS (Figure 2).
103 Synthetic efforts began with the preparation of the three
s1 104 requisite fatty acids 7−9 (Scheme 1). Synthesis commenced
105 with monobenzylation of 1,8-octanediol and 1,10-decanediol to
106 provide alcohols 10 and 11, respectively. Subsequent Swern
107 oxidation and olefination with either isobutyl(triphenyl)-
108 phosphonium bromide or isoamyl(triphenyl)phosphonium
109 bromide yielded olefins 12−14 in 60−66% yield over two
110steps. Simultaneous hydrogenation of the olefin and hydro-
111genolysis of the benzyl ether, followed by Dess-Martin
112oxidation, afforded the corresponding aldehydes. These were
113next subjected to a second Wittig olefination with ethyl-
114(triphenyl)phosphoranylidene acetate, to furnish (E)-α,β-
115unsaturated esters 15−17 in 58−62% overall yield over the
116three steps. Finally, hydrolysis of the ethyl ester provided the
117requisite fatty acids 7−9 in quantitative yield.
118Next, we turned our attention to synthesis of the common
119 s2side-chain- and backbone-protected cyclic peptide 5 (Scheme
120 s22). Beginning with 2-chlorotrityl chloride-functionalized
121polystyrene resin, loading of the C-terminal proline residue,
122followed by iterative SPPS using commercially available N-
123Fmoc and side-chain-protected amino acids, afforded the
124requisite resin-bound undecapeptide 18. Glycine residues
125were incorporated as their corresponding 2,4-dimethoxybenzyl
126(Dmb)-protected variants to prevent aspartimide formation
127during Fmoc deprotection steps and to function as turn-
128inducing elements for the subsequent cyclization. Furthermore,
129the L-Dap residue was incorporated as the side chain Alloc-
130protected variant to facilitate orthogonal deprotection on the
Figure 1. Glycinocins A−D with key structural features highlighted in
red (Ca2+-binding motif), green (nonproteinogenic amino acids), and
blue (fatty acyl moiety).
Figure 2. Proposed retrosynthesis of glycinocins A−C (1−3).
Scheme 1. Synthesis of Fatty Acids 7−9
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131 solid phase. Thus, following assembly of the peptide chain, the
132 Alloc group was removed via treatment of the resin-bound
133 peptide with a solution of Pd(PPh3)4 and PhSiH3 in CH2Cl2.
134 Next, the peptide was treated with a mildly acidic solution of
135 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) in CH2Cl2 to facili-
136 tate selective cleavage from the resin without affecting the side
137 chain protecting groups on the peptide. Gratifyingly, macro-
138 lactamization could be smoothly effected by treatment with 4-
139 (4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium tetra-
140 fluoroborate (DMTMM·BF4) with iPr2NEt at high dilution
141 (0.01 M). After Fmoc deprotection and purification by reverse-
142 phase HPLC, the desired protected cyclic peptide 5 was
143 obtained in an excellent yield of 42% over 36 linear steps
144 (based on the original resin loading).
145 The final steps in the synthesis involved coupling cyclic
146 peptide 5 to fatty acids 7−9 followed by global deprotection.
147 Toward this end, the protected cyclic peptide 5 was treated
148 with a solution of each of the fatty acids 7−9 (2 equiv) in DMF
149 using 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydro-
150 chloride (EDC·HCl) as a coupling reagent in the presence of
151 iPr2NEt. The couplings were monitored by LC-MS, which
152 indicated that the reactions had reached completion after 16 h.
153 At this point, the reaction mixtures were concentrated to
154dryness and then treated with a mixture of TFA, iPr3SiH, and
155H2O (18:1:1 v/v/v) to effect acidolytic deprotection of the
156backbone Dmb and tBu side chain protecting groups.
157Subsequent purification by reverse-phase HPLC afforded
158glycinocins A−C (1−3) in 43−49% yield. Pleasingly, the
159NMR spectra and optical rotations of the synthetic natural
160products were in close agreement with those reported for
161isolated glycinocin A−C (see Supporting Information).16
162Having successfully synthesized the target natural products,
163we next investigated the antimicrobial activity of 1−3 against
164both Gram-positive and Gram-negative bacterial strains, with
165 t1and without the presence of Ca2+ in the media (Table 1).
166Specifically, growth inhibition of Gram-positive Bacillus subtilis
167168, methicillin susceptible Staphylococcus aureus (MSSA)
168(ATCC 29213), Enterococcus faecium (ATCC 6569), as well
169as Gram-negative Pseudomonas aeruginosa (ATCC 27853) were
170assessed using a high-throughput screening assay reported
171previously18 using cation adjusted Mueller-Hinton broth
172(MHB), containing 0 or 1.25 mM Ca2+ (see Supporting
173Information for details). In addition to synthetic glycinocins
174A−C (1−3), rifampicin, daptomycin, vancomycin, and
175gentamicin were included as controls.
Scheme 2. Synthesis of Glycinocins A−C
Table 1. MIC Values in μM (and μg/mL) of Synthetic Glycinocins A−C (1−3) and Control Antibiotics with and without the
Presence of Ca2+ against S. aureus and B. subtilis
S. aureus B. subtilis
species 0 mM Ca2+ 1.25 mM Ca2+ 0 mM Ca2+ 1.25 mM Ca2+
glycinocin A (1) >66 (>82) 11 (14) >66 (>82) 17 (21)
glycinocin B (2) >66 (>83) 5.5 (6.9) >66 (>83) 8.3 (10)
glycinocin C (3) >66 (>81) 17 (21.0) >66 (>81) 11 (14)
rifampicin 0.006 (0.005) 0.008 (0.007) 0.15 (0.12) 0.11 (0.091)
daptomycin 22 (36) 0.34 (0.55) 22 (36) 0.94 (1.5)
vancomycin 0.94 (1.4) 0.51 (0.74) 0.097 (0.14) 0.11 (0.16)
gentamicin 1.3 (0.62) 4.4 (2.1) 0.39 (0.19) 0.064 (0.031)
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176 All synthetic glycinocins 1−3 exhibited antimicrobial activity
177 against Gram-positive S. aureus and B. subtilis in the presence of
178 1.25 mM Ca2+ (physiological concentration) with MICs
179 ranging from 5.5 to 17 μM; however, the natural products
180 lost this activity in the absence of Ca2+ in the media. All
181 compounds were inactive against Gram-positive E. faecium and
182 Gram-negative P. aeruginosa both in the presence and in the
183 absence of Ca2+ (see Supporting Information for data). To
184 date, only isolated glycinocin A (1) has been assessed for
185 antimicrobial activity.8,12 Importantly, the Ca2+ dependency and
186 activities observed for synthetic glycinocins A−C (1−3) in this
187 study are consistent with the prior data reported for 1. It is
188 interesting to note that the order of observed antimicrobial
189 activity is 3 < 1 < 2, which reflects the increasing chain length
190 of the fatty acyl substituent. It is therefore tempting to speculate
191 that the increasing lipophilicity of the fatty acyl substituent aids
192 in binding to the proposed undecaprenyl phosphate target of
193 the natural products. This work therefore provides a potential
194 direction for analogue design, which will be the subject of
195 future work in our laboratories.
196 In summary, a high yielding total synthesis of glycinocins A−
197 C (1−3) has been accomplished by utilizing a highly divergent
198 late-stage acylation of a common cyclic peptide precursor. The
199 natural products exhibited calcium-dependent antimicrobial
200 activity against the Gram-positive pathogens S. aureus and B.
201 subtilis. Current work in our laboratory is focused on the
202 preparation of glycinocin analogues to improve activity and to
203 better understand structure−activity relationships.
204 ■ EXPERIMENTAL SECTION
205 General Procedures. Commercial materials, including solvents,
206 were used as received unless otherwise noted. Anhydrous MeOH,
207 DMF, and CH2Cl2 were obtained from a PURE SOLV solvent
208 dispensing unit. Solution-phase reactions were carried out under an
209 atmosphere of dry nitrogen or argon, unless otherwise specified.
210 Flash column chromatography was performed using 230−400 mesh
211 Kieselgel 60 silica eluting with gradients as specified. Analytical thin
212 layer chromatography (TLC) was performed on commercially
213 prepared silica plates (Merck Kieselgel 60 0.25 mm F254).
214 1H NMR, 13C NMR, and 2D NMR spectra were recorded at 300 K
215 using a Bruker AVANCE600, DRX500, DRX400, or AVANCE300
216 spectrometer. Chemical shifts are reported in parts per million (ppm)
217 and are referenced to solvent residual signals: CDCl3 δ 7.26 [
1H] and
218 δ 77.16 [13C] and DMSO-d6 δ 2.50 [
1H] and δ 39.52 [13C]. 1H NMR
219 data are reported as chemical shifts, multiplicity (s = singlet, d =
220 doublet, t = triplet, q = quartet, dd = doublet of doublets, ddd =
221 doublet of doublet of doublets, m = multiplet, br = broad), coupling
222 constant (J Hz), and assignment where possible. 1D peak assignments
223 for cyclic peptide 5 were made using COSY, TOCSY, HSQC, and
224 HMBC where appropriate. Peak assignments for synthetic glycinocins
225 A−C (1−3) were made using HSQC and HMBC through comparison
226 with literature assignments.16
227 High-resolution ESI+ mass spectra were measured on a Bruker−
228 Daltonics Apex Ultra 7.0T Fourier transform mass spectrometer
229 (FTICR). Low-resolution ESI mass spectra were obtained on a
230 Shimadzu 2020 ESI mass spectrometer operating in positive ion mode.
231 Infrared (IR) absorption spectra were recorded on a Bruker ALPHA
232 spectrometer with attenuated total reflection (ATR) capability.
233 Compounds were deposited as films on the ATR plate via a CH2Cl2
234 solution. Optical rotations were recorded at ambient temperature (293
235 K) on a Perkin-Elmer 341 polarimeter at 589 nm (sodium D line) with
236 a cell path length of 1 dm, and the concentrations are reported in g/
237 100 mL.
238 Preparative reverse-phase HPLC was performed using a Waters 600
239 multisolvent delivery system and pump with Waters 486 tunable
240 absorbance detector operating at 214 nm. Analytical reverse-phase
241HPLC was performed on a Waters 2695 separation module equipped
242with a 2996 DAD detector operating at 214 nm.
243Monobenzylated Alcohols 10 and 11.
244Sodium hydride (60% oil dispersion, 1.05 equiv) was suspended in
245DMF (20 mL) and subsequently cooled to 0 °C. A solution of
246alkanediol (1 equiv) in THF/DMF (1:2 v/v, 20 mL) was then slowly
247added, and the reaction mixture was stirred at 0 °C for 2 h. Benzyl
248bromide (1.05 equiv) was then added dropwise to the cooled reaction
249mixture. Following addition, the reaction mixture was warmed to rt
250and stirred for 16 h. Upon completion, the reaction mixture was
251cooled to 0 °C and quenched with H2O (20 mL). The mixture was
252then partitioned between EtOAc (150 mL) and H2O (150 mL). The
253organic extract was washed with H2O (5 × 100 mL), followed by
254brine, and dried (MgSO4). The solvent was then removed by rotary
255evaporation, and the crude mixture was purified by column
256chromatography to yield both the dibenzylated and monobenzylated
257products (an eluent gradient of 10−20 vol % EtOAc in hexane
258provided the dibenzylated product, whereas a gradient of 20−30 vol %
259EtOAc in hexane provided the desired monobenzylated alcohol 10 or
26011).
2618-(Benzyloxy)-1-octanol (10): Prepared from 2.00 g (13.7 mmol)
262of 1,8-octanediol; yield = 1.53 g, 47%, colorless oil; Rf [30 vol %
263EtOAc/hexane] = 0.4; IR (thin film) νmax = 3350, 2928, 2855, 1718,
2641703, 1453, 1362, 1314, 1275, 1097, 1071, 1056, 1027, 737, 713, 697,
265611 cm−1; 1H NMR (CDCl3, 300 MHz) δ 7.55−7.23 (5H, m,
266aromatic CH), 4.48 (2H, s, benzylic CH2), 3.61 (2H, t, J 6.6 Hz,
267CH2OH), 3.44 (2H, t, J 6.6 Hz, CH2OBn), 2.61 (1H, s, OH), 1.59−
2681.52 (4H, m), 1.40−1.30 (8H, m) ppm. Data are in agreement with
269that reported by Madda et al.19 and Subba Reddy et al.20
27010-(Benzyloxy)-1-decanol (11): Prepared from 1.20 g (6.89 mmol)
271of 1,10-decanediol; yield = 879 mg, 48%, colorless oil; Rf [30 vol %
272EtOAc/hexane] = 0.4; IR (thin film) νmax = 3366, 2926, 2853, 1454,
2731362, 1205, 1100, 1074, 1058, 1028, 735, 697 cm−1; 1H NMR (400
274MHz, CDCl3) δ 7.32−7.25 (5H, m, aromatic CH), 4.49 (2H, s,
275benzylic CH2), 3.62 (2H, t, J 6.5 Hz, CH2OH), 3.45 (2H, t, J 6.5 Hz,
276CH2OBn), 1.62−1.53 (4H, m, 2 × CH2), 1.39−1.28 (12H, m, 6 ×
277CH2) ppm; LRMS (ESI+) m/z 287 [(M + Na)
+, 100%]. Data are in
278agreement with that reported by Mash et al.21 and Penov Gasi et al.22
279Alkenes 12−14.
280To a solution of oxalyl chloride (3 equiv) in CH2Cl2 (15 mL) at −78
281°C was added dimethylsulfoxide (3.3 equiv). The mixture was stirred
282at −78 °C for 30 min before the slow addition of a solution of benzyl
283alcohol 10 or 11 (1 equiv) in CH2Cl2 (10 mL). The mixture was
284stirred at −78 °C for a further 30 min. Triethylamine (5.1 equiv) was
285finally added to the cooled reaction mixture, which was then warmed
286to rt and stirred for 1 h. The reaction was quenched with H2O (50
287mL) and the resulting mixture extracted into chloroform (3 × 50 mL).
288The combined organic extracts were washed with brine, dried over
289anhydrous magnesium sulfate, and the solvent removed by rotary
290evaporation. The resulting aldehyde was used in the next step without
291further purification.
292n-Butyllithium (2.5 M, 2 equiv) was added slowly to a cooled (−10
293°C) suspension of isobutyl- or isoamyl(triphenyl)phosphonium
294bromide (1.2 equiv) in THF (2.8 mL). While being stirred at −10
295°C for 1 h, the reaction mixture slowly transformed from a white
296suspension to an orange solution. A solution of the aldehyde from the
297previous step (1 equiv) in THF (1 mL) was then added slowly to the
298yellow solution at −10 °C. The reaction mixture was stirred at −10 °C
299for 10 min and at rt for a further 2 h. After this time, cold H2O (0 °C)
300was added slowly to quench the reaction, which was then extracted
301with EtOAc (3 × 15 mL). The combined organic extracts were washed
302with brine, dried over anhydrous magnesium sulfate, and the solvent
303removed by rotary evaporation. Finally, purification by column
304chromatography (an eluent gradient of 0−3 vol % EtOAc in hexane
305was used to remove any byproducts, followed by a gradient of 4−10%
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306 EtOAc in hexane to yield the purified alkenes) provided the desired
307 alkene products 12−14.
308 (E/Z)-11-(Benzyloxy)-2-methylundec-3-ene (12): Prepared from
309 1.98 mmol of 8-(benzyloxy)-1-octanol 10 and isobutyl(triphenyl)-
310 phosphonium bromide; yield = 0.36 g, 66%, ∼5:1 inseparable
311 diasteromeric mixture, colorless oil; Rf [10 vol % EtOAc/hexane] =
312 0.4; IR (thin film) νmax = 3370, 2952, 2925, 2855, 1721, 1466,1453,
313 1274, 1113, 1070, 1027, 712 cm−1; 1H NMR (400 MHz, CDCl3)
314 diastereomeric mixture δ 7.34−7.25 (5H, m, aromatic CH), 5.36−5.14
315 (2H, m, CHCH), 4.50 (2H, s, benzylic CH2), 3.46 (2H, t, J 6.7 Hz,
316 CH2OBn), 2.58, 2.22 (1H, 2m, CH(CH3)2), 2.02, 1.95 (2H, 2m,
317 CHCHCH2), 1.65−1.59 (2H, m, CH2), 1.40−1.26 (8H, m, 4 ×
318 CH2), 0.96, 0.94 (6H, 2d, J 6.6 Hz, CH(CH3)2) ppm;
13C NMR (100
319 MHz, CDCl3) major isomer δ 138.7, 137.5, 128.3, 127.6, 127.5, 72.9,
320 70.5, 29.9, 29.8, 29.4, 29.2, 27.3, 26.4, 26.2, 23.2 ppm; LRMS (ESI+)
321 m/z 313 [(M + K)+, 100%]; HRMS (ESI+) calcd for C19H30O1Na [M
322 + Na]+, 297.2189; found [M + Na]+, 297.2193.
323 (E/Z)-12-(Benzyloxy)-2-methyldodec-4-ene (13): Prepared from
324 3.59 mmol of 8-(benzyloxy)-1-octanol and isoamyl(triphenyl)-
325 phosphonium bromide; yield = 0.64 g, 62%, ∼5:1 inseparable
326 diasteromeric mixture, colorless oil; Rf [10 vol % EtOAc/hexane] =
327 0.4; IR (thin film) νmax = 2951, 2926, 2854, 1721, 1463, 1365, 1273,
328 1099, 1028, 734, 697 cm−1; 1H NMR (400 MHz, CDCl3)
329 diastereomeric mixture δ 7.36−7.27 (5H, m, aromatic CH), 5.45−
330 5.16 (2H, m, CHCH), 4.52 (2H, s, benzylic CH2), 3.54, 3.49 (2H,
331 2t, J 6.6 Hz, CH2OBn), 2.05−1.87 (4H, m, 2 × CHCHCH2), 1.67−
332 1.59 (3H, m, CH(CH3)2, CH2), 1.42−1.29 (10H, m, 5 x CH2), 0.92,
333 0.89 (6H, 2d, J 6.6 Hz, CH(CH3)) ppm; LRMS (ESI+) m/z 311 [(M
334 + Na)+, 100%]; HRMS (ESI+) calcd for C20H32ONa [M + Na]
+,
335 311.2345; found [M + Na]+, 311.2348. Data are in agreement with
336 that reported by Shiori and Irako.23
337 (E/Z)-13-(Benzyloxy)-2-methyltridec-3-ene (14): Prepared from
338 3.20 mmol of 10-(benzyloxy)decanol and isobutyl(triphenyl)-
339 phosphoium bromide; yield = 0.58 g, 60%, ∼5:1 inseparable
340 diasteromeric mixture, colorless oil; Rf [10 vol % EtOAc/hexane] =
341 0.4; IR (thin film) νmax = 2925, 2854, 1463, 1438, 1361, 1202, 1117,
342 1102, 733, 696, 542 cm−1; 1H NMR (500 MHz, CDCl3) diastereomeric
343 mixture δ 7.34−7.33 (4H, m, aromatic ortho/meta-CH), 7.28 (1H, m,
344 aromatic para-CH), 5.36−5.15 (2H, m, CHCH), 4.50 (2H, s,
345 benzylic CH2), 3.46 (2H, t, J 6.7 Hz, CH2OBn), 2.59, 2.22 (1H, 2m,
346 CH(CH3)2), 2.02, 1.96 (1H, 2m, CHCHCH2), 1.64−1.58 (2H, m,
347 CH2), 1.38−1.28 (12H, m, 6 × CH2), 0.96, 0.94 (6H, 2d, J = 6.7 Hz,
348 CH(CH3)2) ppm;
13C NMR (125 MHz, CDCl3) major isomer δ 138.9,
349 137.6, 128.5, 127.8, 127.7, 127.6, 73.0, 70.7, 30.1, 29.9, 29.7, 29.6, 29.4,
350 27.5, 26.6, 26.3, 23.4 ppm; LRMS (ESI+) m/z 325 [(M+Na)+, 100%];
351 HRMS (ESI+) calcd for C21H34ONa [M + Na]
+, 325.2502; found [M
352 + Na]+, 325.2505.
353 Alkenoates 15−17.
354 A mixture of alkenes 12−14 and 5 wt % palladium on carbon (0.05
355 equiv) in methanol was stirred under a H2 atmosphere at rt for 3 h.
356 The reaction mixture was then filtered over Celite, and the resulting
357 filtrate was concentrated to yield the desired alcohol, which was used
358 in the next step without further purification. A solution of the above
359 alcohol (1 equiv) and Dess-Martin periodinane (1.5 equiv) in wet
360 CH2Cl2 was stirred at rt for 1 h. Upon completion, saturated aqueous
361 sodium hydrogen carbonate and sodium thiosulfate (1:1 v/v) were
362 added, and the mixture was stirred for 20−30 min, until the lower
363 organic layer was observed to transform from a white suspension to a
364 colorless solution. The immiscible mixture was then separated, and the
365 aqueous layer was further extracted into CH2Cl2 (3×). The combined
366 CH2Cl2 extracts were finally dried over anhydrous magnesium sulfate
367 and concentrated to yield the desired aldehyde, which was used in the
368 next step without further purification. A mixture of the above aldehyde
369 (1 equiv) and ethyl 2-(triphenylphosphoranylidene)acetate (1.5 equiv)
370 in CH2Cl2 was stirred at rt for 16 h. The solvent was removed by
371 rotary evaporation, and the crude residue was purified by column
372chromatography (0−5 vol % EtOAc in hexane) to yield pure α,β-
373unsaturated ethyl ester 15−17.
374Ethyl (E)-12-Methyltridec-2-enoate (15): Prepared from 0.46 mmol
375of (E/Z)-11-(benzyloxy)-2-methylundec-3-ene (12); yield = 66 mg,
37656% over three steps, colorless oil; Rf [5 vol % EtOAc/hexane] = 0.2;
377IR (thin film) νmax = 3000, 2954, 2627, 2826, 2044, 1724, 1694, 1651,
3781445 cm−1; 1H NMR (400 MHz, CDCl3) δ 6.96 (1H, dt, J = 7.0 Hz
379and 15.6 Hz, EtO2CCHCH), 5.81 (1H, dt, J = 1.6 Hz and 15.6 Hz,
380EtO2CCHCH), 4.18 (2H, q, J = 7.1 Hz, CH3CH2O), 2.17 (2H, m,
381CHCHCH2), 1.51 (1H, m, CH(CH3)2), 1.48−1.41 (2H, m, CH2),
3821.33−1.24 (13H, m, 5 × CH2 and CH3CH2O), 1.14 (2H, m, CH2),
3830.86 (6H, d, J = 6.6 Hz, CH(CH3)2) ppm;
13C NMR (100 MHz,
384CDCl3) δ 167.0 (Cq=O); 149.7 (EtO2CCHCH), 121.4
385(EtO2CCHCH), 60.3 (OCH2CH3), 39.2, 32.4, 30.0, 29.7, 29.6,
38629.3, 28.2 (7 × CH2), 28.1 (CH(CH3)2), 27.5 (CH2), 22.8
387(CH(CH3)2), 14.4 (OCH2CH3) ppm; LRMS (ESI+) m/z 277 [(M
388+ Na)+, 100%]; HRMS (ESI+) calcd for C16H30O2Na [M + Na]
+,
389277.2138; found [M + Na]+, 277.2141.
390Ethyl (E)-13-Methyltetradec-2-enoate (16): Prepared from 0.23
391mmol of (E/Z)-12-(benzyloxy)-2-methyldodec-4-ene (13); yield = 39
392mg, 61% over 3 steps, colorless oil; Rf [5 vol % EtOAc/hexane] = 0.2;
393IR (thin film) νmax = 2953, 2925, 2854, 1723, 1655, 1466, 1367, 1309,
3941265, 1180, 1045, 979 cm−1; 1H NMR (400 MHz, CDCl3) δ 6.96
395(1H, dt, J = 7.0 Hz and 15.6 Hz, EtO2CCHCH), 5.81 (1H, dt, J =
3961.6 Hz and 15.6 Hz, EtO2CCHCH), 4.18 (2H, q, J = 7.1 Hz,
397CH3CH2O), 2.19 (2H, m, CHCHCH2), 1.56−1.41 (3H, m,
398CH(CH3)2 and CH2), 1.33−1.24 (15H, m, 6 × CH2 and
399CH3CH2O), 1.15 (2H, m, CH2), 0.86 (6H, d, J = 6.6 Hz, CH(CH3)2)
400ppm; LRMS (ESI+) m/z 291 [(M+Na)+, 100%]; HRMS (ESI+) calcd
401for C17H32O2Na [M + Na]
+, 291.2295; found [M + Na]+, 291.2297.
402Data are in agreement with that reported by Shiori et al.23 and Suami
403et al.24
404Ethyl (E)-14-Methylpentadec-2-enoate (17): Prepared from 0.13
405mmol of (E/Z)-13-(benzyloxy)-2-methyltridec-3-ene (14); yield = 23
406mg, 62% over three steps, colorless oil; Rf [5 vol % EtOAc/hexane] =
4070.2; IR (thin film) νmax = 2956, 2920, 2859, 1731, 1649 cm
−1; 1H
408NMR (500 MHz, CDCl3) δ 6.96 (1H, dt, J = 7.0 Hz and 15.6 Hz,
409EtO2CCHCH), 5.80 (1H, dt, J = 1.6 Hz and 15.6 Hz, EtO2CCH
410CH), 4.18 (2H, q, J = 7.1 Hz, CH3CH2O), 2.19 (2H, m, CH
411CHCH2), 1.55−1.41 (3H, m, CH(CH3)2 and CH2), 1.33−1.24 (17H,
412m, 7 × CH2 and CH3CH2O), 1.15 (2H, m, CH2), 0.86 (6H, d, J = 6.6
413Hz, CH(CH3)2) ppm;
13C NMR (125 MHz, CDCl3) δ 167.0 (CO),
414149.7 (EtO2CCHCH), 121.4 (EtO2CCHCH), 60.3 (OCH2CH3),
41539.2 (CH2CH(CH3)2), 32.4 (CHCHCH2), 30.1, 29.8, 29.8, 29.7,
41629.5, 29.3, 28.2 (7 × CH2), 28.1 (CH(CH3)2), 27.6 (CH2), 22.8
417(CH(CH3)2), 14.4 (OCH2CH3) ppm; LRMS (ESI+) m/z 305 [(M +
418Na)+, 100%]; HRMS (ESI+) calcd for C18H34O2Na [M + Na]
+,
419305.2451; found [M + Na]+, 305.2453.
420Alkenoic Acids 7−9.
421A solution of α,β-unsaturated ethyl esters 15−17 in NaOH (1 M) and
422tert-butyl alcohol (1:1 v/v, 2 mL) was stirred at 60 °C for 6 h. After
423being cooled to rt, the reaction was acidified with HCl(aq) (0.5 M, 2
424mL) and extracted into CH2Cl2 (3 × 3 mL). The combined organic
425extracts were washed with brine, dried over anhydrous magnesium
426sulfate, and concentrated to dryness to yield the α,β-unsaturated fatty
427acids 7−9, which were used without further purification.
428(E)-12-Methyltridec-2-enoic Acid (7): Prepared from 47 mg (0.19
429mmol) of ethyl (E)-12-methyltridec-2-enoate 15; yield = 41 mg, 98%,
430colorless oil; IR (thin film) νmax = 2951, 2924, 2853, 1696, 1650, 1466,
4311420, 1308, 1285, 980, 939 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.08
432(1H, dt, J = 7.3 Hz and 14.6 Hz, HO2CCHCH), 5.81 (1H, d, J =
43315.5 Hz, HO2CCHCH), 2.23 (2H, m, CHCHCH2), 1.56−1.43
434(3H, m, CH2, CH(CH3)2), 1.33−1.24 (10H, m, 5 × CH2), 1.15 (2H,
435m, CH2), 0.85 (6H, d, J = 6.5 Hz, CH(CH3)2) ppm;
13C NMR (100
436MHz, CDCl3) δ 171.2 (CO), 152.6 (HO2CCHCH), 120.5
437(HO2CCHCH), 39.2 (CH2CH(CH3)2), 32.5 (CHCHCH2), 30.0
438(CH2), 29.7 (CH2), 29.5 (CH2), 29.3 (CH2), 28.1 (CH2), 28.0
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439 (CH(CH3)2), 27.5 (CH2), 22.8 (CH(CH3)2) ppm; LRMS (ESI+) m/z
440 225 [(M − H)+, 100%]; HRMS (ESI+) calcd for (C14H26O2)2Na [2M
441 + Na]+, 476.3792; found [2M + Na]+, 476.3792.
442 (E)-13-Methyltetradec-2-enoic Acid (8): Prepared from 28 mg
443 (0.10 mmol) of ethyl (E)-13-methyltetradec-2-enoate 16; yield = 24
444 mg, 98%, colorless oil; IR (thin film) νmax = 2955, 2923, 2853, 1722,
445 1699, 1464 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.08 (1H, dt, J = 7.0
446 and 15.5 Hz, HO2CCHCH), 5.83 (1H, dt, J = 1.5 and 15.6 Hz,
447 HO2CCHCH), 2.23 (2H, m, CHCHCH2), 1.56−1.43 (3H, m,
448 CH(CH3)2 and CH2), 1.34−1.24 (12H, m, 6 × CH2), 1.15 (2H, m,
449 CH2), 0.86 (6H, d, J = 6.6 Hz, CH(CH3)2) ppm; LRMS (ESI+) m/z
450 239 [(M + H)+, 100%]; HRMS (ESI+) calcd for C15H27O2 [M − H]−,
451 239.2017; found [M − H]−, 239.2020. Data are in agreement with that
452 reported by Suami et al.24
453 (E)-14-Methylpentadec-2-enoic Acid (9): Prepared from 15 mg (53
454 μmol) of (E)-14-methylpentadec-2-enoate 17; yield = 13 mg, 96%,
455 colorless oil; IR (thin film) νmax = 2952, 2925, 2854, 1698, 1651, 1466,
456 1421, 1308, 1285 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.08 (1H, dt, J
457 = 15.6 and 7.0 Hz, HO2CCHCH), 5.83 (1H, dt, J = 15.6 and 1.5
458 Hz, HO2CCHCH), 2.23 (2H, m, CHCHCH2), 1.57−1.43 (3H,
459 m, CH(CH3)2 and CH2), 1.33−1.24 (14H, m, 7 × CH2), 1.15 (2H, m,
460 CH2), 0.86 (6H, d, J = 6.6 Hz, CH(CH3)2) ppm;
13C NMR (100
461 MHz, CDCl3) δ 170.3 (CqO), 152.5 (HO2CCHCH), 120.3
462 (HO2CCHCH), 39.2 (CH2CH(CH3)2), 32.5 (HO2CCH
463 CHCH2), 30.1, 29.8, 29.8, 29.7, 29.5, 29.3, 28.1 (7 × CH2), 28.0
464 (CH(CH3)2), 27.6 (CH2), 22.8 (CH(CH3)2) ppm; LRMS (ESI+) m/z
465 277 [(M + Na)+, 100%]; HRMS (ESI+) calcd for C16H30O2Na [M +
466 Na]+, 277.2138; found [M + Na]+, 277.2141.
467 Cyclic Peptide 5.
468 Resin Loading. 2-Chlorotrityl chloride resin (100−200 mesh) with
469 1% divinylbenzene (474 mg, 1.14 mmol g−1, 0.540 mmol, 1 equiv) was
470 allowed to swell in dry CH2Cl2 (5 mL) for 30 min. After being
471 drained, the resin was suspended in a solution of Fmoc-L-Pro-OH
472 (364 mg, 1.08 mmol, 2 equiv) and iPr2NEt (376 μL, 2.16 mmol, 4
473 equiv) in DMF/CH2Cl2 (1:1 v/v, 10 mL) and shaken for 16 h. The
474 resin was subsequently washed with DMF (5 × 5 mL), CH2Cl2 (5 × 5
475 mL), and DMF (5 × 5 mL) before being capped with a mixture of
476 CH2Cl2/MeOH/iPr2NEt (17:2:1 v/v/v, 5 mL) for 1 h. The resin was
477 again washed with DMF (5 × 5 mL), CH2Cl2 (5 × 5 mL), and DMF
478 (5 × 5 mL).
479 Fmoc-SPPS. An iterative strategy of Fmoc deprotection and amino
480 acid coupling was repeated sequentially for Fmoc-L-Ile-OH, Fmoc-D-
481 allo-Thr(tBu)-OH, Fmoc-(Dmb)Gly-OH, Fmoc-L-Asp(tBu)-OH,
482 Fmoc-(Dmb)Gly-OH, Fmoc-L-Asp(tBu)-OH, Fmoc-(Dmb)Gly-OH,
483 Fmoc-D-Pip-OH, Fmoc-L-Dap(Alloc)-OH, and Fmoc-L-Asp(tBu)-OH.
484 Fmoc Deprotection: A solution of 10 vol % piperidine in DMF (5
485 mL) was added to the resin and shaken for 3 min (2×). The resin was
486 subsequently washed with DMF (5 × 5 mL), CH2Cl2 (5 × 5 mL), and
487 DMF (5 × 5 mL). Following the initial Fmoc deprotection, the
488 efficiency of amino acid loading was determined by spectroscopic
489 measurement of the resulting fulvene piperidine adduct at λ = 301 nm
490 (ε = 7800 M−1 cm−1). Caution: Resin cross-linking was found to occur
491 upon extended standing af ter the initial Fmoc deprotection (as
492 evidenced by resin clumping and the complete inability to acylate the
493 resin-bound proline residue). Therefore, it was crucial to couple the
494 second amino acid residue immediately af ter the initial Fmoc
495 deprotection.
496Standard Amino Acid Coupling: For standard amino acids (Fmoc-
497L-Ile-OH and Fmoc-L-Asp(tBu)-OH), a solution of the protected
498amino acid (2.70 mmol, 5 equiv), DIC (423 μL, 2.70 mmol, 5 equiv),
499and oxyma (384 mg, 2.70 μmol, 5 equiv) in DMF (5 mL) was added
500to the resin and shaken. After 1 h, the resin was washed with DMF (5
501× 5 mL), CH2Cl2 (5 × 5 mL), and DMF (5 × 5 mL).
502Nonstandard Amino Acid Coupling: For Fmoc-D-allo-Thr(tBu)-
503OH, Fmoc-(Dmb)Gly-OH, Fmoc-D-Pip-OH, Fmoc-L-Dap(Alloc)-
504OH), a solution of the protected amino acid (0.810 mmol, 1.5
505equiv), DIC (127 μL, 0.810 mmol, 1.5 equiv), and oxyma (115 mg,
5060.810 mmol, 1.5 equiv) in DMF (4 mL) were added to the resin and
507shaken for 4 h. The resin was washed with DMF (5 × 5 mL), CH2Cl2
508(5 × 5 mL), and DMF (5 × 5 mL).
509This strategy was followed to yield the resin-bound linear peptide:
510Fmoc-L-Asp(tBu)-L-Dap(Alloc)-D-Pip-(Dmb)Gly-L-Asp(tBu)-(Dmb)-
511Gly-L-Asp(tBu)-(Dmb)Gly-D-allo-Thr(tBu)-L-Ile-L-Pro-resin.
512Alloc Deprotection. A solution of Pd(PPh3)4 (624 mg, 0.540 mmol,
5131 equiv) and PhSiH3 (1.1 mL, 8.6 mmol, 16 equiv) in CH2Cl2 (20
514mL) was added to the resin and shaken for 1 h. The resin was
515subsequently washed with CH2Cl2 (5 × 5 mL), DMF (5 × 5 mL), and
516CH2Cl2 (5 × 5 mL).
517Cleavage. A solution of 30 vol % HFIP in CH2Cl2 (20 mL) was
518added to the resin and shaken for 30 min before the resin was filtered
519off and rinsed with CH2Cl2. This process was repeated a further three
520times for 10 min, and the combined filtrates were concentrated in
521vacuo. The residue was azeotroped three times with CH2Cl2 and dried
522in vacuo to yield the crude linear peptide as an off-white foam.
523Macrolactamization. iPr2NEt (189 μL, 1.08 mmol, 2 equiv) was
524added to a solution of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-
525morpholinium tetrafluoroborate (DMTMM·BF4, 192 mg, 0.651 mmol,
5261.2 equiv) and the crude linear peptide (0.540 mmol, 1 equiv) in DMF
527(50 mL, 0.01 M). The resulting reaction mixture was stirred at rt for
52816 h before the solvent was removed in vacuo.
529Final Fmoc Deprotection and Purification. The crude Fmoc-
530protected cyclic peptide was dissolved in a solution of 10 vol %
531piperidine in MeCN (10 mL), and the mixture was stirred for 30 min
532at rt. The mixture was then concentrated in vacuo and azeotroped with
533toluene (2×) and CH2Cl2 (2×). Finally, the residue was dissolved in a
534mixture of MeCN and H2O, filtered, and purified by preparative
535reverse-phase HPLC (Waters Sunfire C18 5 μm, 30 × 150 mm, 40
536mL·min−1, 30−100% MeCN [0.1% TFA] in H2O [0.1% TFA] over 30
537min).
538The above steps afforded pure cyclic peptide 5 (416 mg, 42% over
53936 steps) as a fluffy white solid following lyophilization: analytical
540HPLC Rt = 4.6 min; 0 to 100% MeCN (0.1% TFA) in H2O (0.1%
541TFA) over 5 min; acquity UPLC BEH C18, 1.7 μm, 2.1 × 50 mm, 214
542nm; sample dissolved in MeCN/H2O 1:1; LRMS (ESI+) 1549 [M −
543Dmb]+, 1700 [M + H]+, 1721 [M + Na]+; HRMS (ESI+) calcd for
544C85H127N12O24Na [M + Na + H]
2+, 861.4487; found, 861.4497; 1H
545NMR (500 MHz, DMSO-d6) δ 8.45 (1H, d, J = 7.7 Hz, Dap NH-2),
5468.31−8.29 (2H, m, Thr NH-2, Asp NH-2), 8.23 (1H, d, J = 7.0 Hz, Ile
547NH-2), 8.07 (1H, d, J = 3.9 Hz, Asp NH-2), 7.73 (3H, d, J = 3.5 Hz,
548Asp NH3
+-2), 7.13−6.74 (4H, m, Dap NH-3, 3 × Dmb ArH), 6.58−
5496.35 (6H, m, 6 × Dmb ArH), 5.42 (1H, m, Pip H2), 5.27 (1H, m, Asp
550H2), 5.15−5.09 (2H, m, Dap H2, DmbCH2a), 4.86 (1H, m, Asp H2),
5514.76−4.71 (2H, m, Gly H2a, DmbCH2a), 4.58 (1H, d, J = 14.6 Hz,
552DmbCH2a), 4.43−4.38 (2H, m, Asp H2, Gly H2a), 4.29 (1H, tapt, J =
5538.9 Hz, Ile H2), 4.06 (1H, tapt, J = 9.2 Hz, Thr H2), 3.97−3.60 (28H,
554m, 3 × DmbCH2b, Pro CH2-5, Gly CH2-2, 6 × Dmb ArOCH3, Thr
555H3, Pip H6a, Pro H2), 3.31−3.25 (2H, m, Dap H3a, Gly H2b), 3.11−
5563.06 (2H, m, Pip H6b, Dap H3b), 3.01−2.88 (3H, m, Gly H2b, 2 ×
557Asp H3a), 2.82−2.56 (3H, m, Asp H3a, 2 × Asp H3b), 2.37 (1H, m,
558Asp H3b), 2.08 (1H, m, Pip H3a), 2.01−1.91 (2H, m, Pro H4a, Pip
559H4a), 1.85−1.71 (3H, m, Pro H4b, Pro H3a, Ile H3), 1.61 (1H, m, Ile
560H4a), 1.64−1.51 (11H, m, Pro H3b, Pip H4b, CO2tBu), 1.45−1.22
561(22H, m, 2 × CO2tBu, Pip H3b, Ile H4b, Pip CH2-5), 1.12−0.83
562(18H, m, Thr CH3-4, OtBu, Ile CH3-4, Ile CH3-5) ppm;
13C NMR
563(125 MHz, DMSO-d6) δ 172.4−166.3 (14 × CO), 160.8−157.9 (6
564× ArO), 131.7, 128.8, 128.5 (3 × ArH), 116.0, 116.0, 115.9 (3 × ArC),
565105.7−104.2 (3 × ArH), 98.6−97.6 (3 × ArH), 81.9, 80.5, 79.8, 73.7
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566 (4 × C(CH3)3), 65.9 (Thr C3), 60.2 (Pro C2), 59.2 (Thr C2), 55.6−
567 55.2 (3 × OCH3) 54.9 (Ile C2), 50.7 (Pip C2), 49.9 (Asp C2), 49.8
568 (Gly C2), 49.2 (Gly C2), 49.0 (Dap C2), 47.6 (Pro C5), 46.4 (Asp
569 C2), 45.9 (Asp C2), 45.7 (DmbCH2), 45.4 (DmbCH2), 44.5 (Gly
570 C2), 43.7 (Pip C6), 43.5 (DmbCH2), 42.3 (Dap C3), 37.2 (Asp C3),
571 35.7 (Ile C3), 35.3 (Asp C3), 35.1 (Asp C3), 28.4−27.6 (4 ×
572 C(CH3)3), 27.9 (Pro C3), 25.9 (Pip C3), 24.9 (Ile C4), 24.8 (Pro
573 C4), 21.0 (Thr C4), 19.8 (Pip C5), 19.7 (Pip C4), 14.3 (Ile C4′), 10.4
574 (Ile C5) ppm. See Supporting Information for tabulated HSQC cross-
575 peaks.
576 Glycinocins A−C (1−3).
577 To an Eppendorf tube containing cyclic peptide trifluoroacetate salt 5
578 (12 mg, 6.6 μmol, 1 equiv) were added a freshly prepared solution of
579 fatty acid 7−9 (2 equiv), iPr2NEt (4.6 μL, 4 equiv), and N-(3-
580 (dimethylamino)propyl)-N′-ethylcarbodiimide hydrochloride (EDC·
581 HCl, 2.5 mg, 2 equiv) in DMF (130 μL, 50 mM with respect to cyclic
582 peptide). The solution was vortexed and allowed to stand at rt for 18
583 h. The solution was concentrated by centrifugal evaporation, and the
584 residue was resuspended in a freshly prepared mixture of TFA/
585 iPr3SiH/H2O (18:1:1 v/v/v) and allowed to stand for 2.5 h at rt. The
586 resulting solution was evaporated under a stream of nitrogen gas, and
587 the residue dissolved in H2O/MeCN (1:1 v/v), filtered, and purified
588 by preparative reverse-phase HPLC (Sunfire C18 5 μm, 19 × 150 mm,
589 7 mL min−1, 20 for 1 min to 100% MeCN (0.1% formic acid) in H2O
590 (0.1% formic acid) over 45 min, UV at 230 nm). In cases where the
591 cyclic lipopeptide coeluted with a nonpeptidic impurity, a second pass
592 purification was performed using buffers of 0.1% TFA in MeCN and
593 H2O under conditions otherwise identical to those stated above. The
594 cyclic lipopeptides 1−3 were obtained as white fluffy solids after
595 lyophilization.
596 Glycinocin A (1): Yield = 3.96 mg, 48% (two steps); [α]D −9.9 (c =
597 0.27, MeOH), lit16 −22; analytical HPLC Rt = 4.0 min; 0 to 100%
598 MeCN (0.1% TFA) in H2O (0.1% TFA) over 5 min; acquity UPLC
599 BEH C18, 1.7 μm, 2.1 × 50 mm, 214 nm; sample dissolved in MeCN/
600 H2O 1:1. LRMS (ESI+) 1247 [M + H]
+, 1269 [M + Na]+; HRMS
601 (ESI+) calcd for C57H90N12O19Na [M + Na]
+ 1269.6337, found
602 1269.6349; 1H NMR (600 MHz, DMSO-d6) δ 8.41−7.67 (9H, m, 9 ×
603 NH), 7.50 (1H, t, J = 5.5 Hz, Dap NH-3), 6.62 (1H, dt, J = 7.0, 15.0
604 Hz, FA H3), 5.93 (1H, d, J = 15.0 Hz, FA H2), 4.79 (1H, m, Pip H2),
605 4.67−4.56 (3H, m, Dap H2, 2 × Asp H2), 4.50 (1H, m, Asp H2),
606 4.39−4.27 (3H, m, Pip H6a, Ile C2, Thr H2), 4.18 (1H, m, Pro H2),
607 3.99 (1H, dd, Gly H2a), 3.83−3.60, (7H, m, Gly H2b, 2 × Gly CH2−
608 2, Thr H3, Pro H5a), 3.59−3.45 (2H, m, Dap H3a, Pro H5b), 3.09
609 (1H, m, Dap H3b), 2.86 (1H, m, Pip H6b), 2.76−2.46 (6H, m, 3 ×
610 Asp CH2−3), 2.18 (1H, m, Pip H3a), 2.11 (2H, m, FA CH2−4), 2.01
611 (1H, m, Pro H3a), 1.92 (1H, m, Pro H4a), 1.81 (1H, m, Pro H4b),
612 1.76−1.70 (2H, m, Pro H3b, Ile H3), 1.59−1.46 (5H, m, Pip H5a, Pip
613 H4a, Pip H3b, Ile H4a, FA H13), 1.41−1.36 (2H, m, FA CH2−5, Pip
614 H4b), 1.28−1.20 (13H, m, FA CH2−6 to CH2−11, Pip H5b), 1.12
615 (2H, m, FA CH2−12), 1.07−0.99 (4H, m, Ile H4b, Thr CH3-4), 0.90−
616 0.77 (12H, m, Ile CH3-4′, CH3-14, CH3-14′, Ile CH3-5) ppm. See
617 Supporting Information for tabulated HSQC cross-peaks and
618 comparison with literature spectra.
619 Glycinocin B (2): Yield = 3.56 mg, 43% (two steps); [α]D −6.2 (c =
620 0.23, MeOH), lit16 −19; analytical HPLC Rt = 4.2 min; 0 to 100%
621 MeCN (0.1% TFA) in H2O (0.1% TFA) over 5 min; acquity UPLC
622 BEH C18, 1.7 μm, 2.1 × 50 mm, 214 nm; sample dissolved in MeCN/
623H2O 1:1; LRMS (ESI+) 1261 [M + H]
+, 1283 [M + Na]+; HRMS
624(ESI+) calcd for C58H92N12O19Na [M + Na]
+ 1283.6494, found
6251283.6506; 1H NMR (600 MHz, DMSO-d6) δ 8.38−7.68 (9H, m, 9 ×
626NH), 7.50 (1H, m, Dap NH-3), 6.62 (1H, dt, J = 7.0, 15.0 Hz, FA
627H3), 5.93 (1H, d, J = 15.0 Hz, FA H2), 4.80 (m, 1H, Pip H2), 4.66−
6284.44 (4H, m, Dap H2, 3 × Asp H2), 4.36−4.17 (4H, m, Pip H6a, Ile
629C2, Thr H2, Pro H2), 3.99−3.60 (8H, m, 3 × Gly CH2-2, Thr H3, Pro
630H5a), 3.56−3.47 (2H, m, Dap H3a, Pro H5b), 3.15 (1H, m, Dap
631H3b), 2.85 (1H, m, Pip H6b), 2.70−2.45 (6H, m, 3 × Asp CH2-3),
6322.19 (1H, m, Pip H3a), 2.12 (2H, m, FA CH2-4), 2.01 (1H, m, Pro
633H3a), 1.92 (1H, m, Pro H4a), 1.82−1.70 (3H, m, Pro H4b, Pro H3b,
634Ile H3), 1.60−1.46 (5H, m, Pip H5a, Pip H4a, Pip H3b, Ile H4a, FA
635H14), 1.42−1.36 (2H, m, FA CH2-5, Pip H4b), 1.28−1.20 (15H, m,
636FA CH2-6 to CH2-12, Pip H5b), 1.13 (2H, m, FA CH2-13), 1.07−1.01
637(4H, m, Ile H4b, Thr CH3-4), 0.91−0.75 (12H, m, Ile CH3-4′, CH3-
63815, CH3-15′, Ile CH3-5) ppm. See Supporting Information for
639tabulated HSQC cross-peaks.
640Glycinocin C (3): Yield 3.98 mg, 49% (two steps); [α]D −13 (c =
6410.28, MeOH), lit13 −13; analytical HPLC Rt = 3.8 min; 0 to 100%
642MeCN (0.1% TFA) in H2O (0.1% TFA) over 5 min; acquity UPLC
643BEH C18, 1.7 μm, 2.1 × 50 mm, 214 nm; sample dissolved in MeCN/
644H2O 1:1; LRMS (ESI+) 1233 [M + H]
+, 1255 [M + Na]+; HRMS
645(ESI+) calcd for C56H88N12O19Na [M + Na]
+ 1255.6181, found
6461255.6191; 1H NMR (600 MHz, DMSO-d6) δ 8.39−7.69 (9H, m, 9 ×
647NH), 7.50 (1H, m, Dap NH-3), 6.63 (1H, dt, J = 6.8, 15.4 Hz, FA
648H3), 5.93 (1H, d, J = 15.4 Hz, FA H2), 4.79 (1H, m, Pip H2), 4.67−
6494.56 (3H, m, Dap H2, 2 × Asp H2), 4.49 (1H, m, Asp H2), 4.37−4.25
650(3H, m, Pip H6a, Ile C2, Thr H2), 4.18 (1H, m, Pro H2), 3.98 (1H,
651dd, Gly H2a), 3.85−3.46, (9H, m, Gly H2b, 2 × Gly CH2-2, Thr H3,
652Pro H5a, Dap H3a, Pro H5b), 3.11 (1H, m, Dap H3b), 2.86 (1H, m,
653Pip H6b), 2.74−2.45 (6H, m, 3 × Asp CH2-3), 2.19 (1H, m, Pip H3a),
6542.12 (2H, m, FA CH2-4), 2.02 (1H, m, Pro H3a), 1.93 (1H, m, Pro
655H4a), 1.84−1.69 (3H, m, Pro H4b, Pro H3b, Ile H3), 1.60−1.46 (5H,
656m, Pip H5a, Pip H4a, Pip H3b, Ile H4a, FA H12), 1.41−1.36 (2H, m,
657FA CH2-5, Pip H4b), 1.28−1.22 (11H, m, FA CH2-6 to CH2-10, Pip
658H5b), 1.13 (2H, m, FA CH2-11), 1.07−1.00 (4H, m, Ile H4b, Thr
659CH3-4), 0.91−0.77 (12H, m, Ile CH3-4′, CH3-13, CH3-13′, Ile CH3-5)
660ppm. See Supporting Information for tabulated HSQC cross-peaks.
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